Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression
Autor: | Yong-Xiang Wang, Qian Huang, Teng-Fei Li, Ming-Li Sun, Yi-Rui Wang, Jun-Ping Ao, Xin-Yan Li |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Male medicine.drug_class Aconitine Stimulation Pharmacology Dynorphins Rats Sprague-Dawley 03 medical and health sciences Subcutaneous injection chemistry.chemical_compound 0302 clinical medicine medicine Animals Rats Wistar ED50 Antihypertensive Agents Analgesics Dose-Response Relationship Drug business.industry Alkaloid Chronic pain Dynorphin A medicine.disease Receptor antagonist Rats Disease Models Animal 030104 developmental biology chemistry Spinal Cord Hyperalgesia Neuropathic pain Neuralgia Female Chronic Pain business 030217 neurology & neurosurgery |
Zdroj: | Psychopharmacology. 235(9) |
ISSN: | 1432-2072 |
Popis: | Lappaconitine is a representative C18-diterpenoid alkaloid extracted from Aconitum sinomontanum Nakai and has been prescribed as a pain relief medicine in China for more than 30 years. This study evaluated its antihypersensitivity activity in the rat models of neuropathic and cancer pains and explored its underlying mechanisms. Subcutaneous injection of cumulative doses of lappaconitine produced dose-dependent mechanical antiallodynia and thermal antihyperalgesia in spinal nerve ligation-induced neuropathic rats. The cumulative dose–response analysis exhibited their Emax values of 53.3 and 58.3% MPE, and ED50 values of 1.1 and 1.6 mg/kg. Single intrathecal lappaconitine dose in neuropathy also dose- and time-dependently blocked mechanical allodynia, with an Emax of 66.1% MPE and an ED50 of 0.8 μg. Its multiple twice-daily intrathecal administration over 7 days did not induce mechanical antiallodynic tolerance. Subcutaneous cumulative doses of lappaconitine also produced dose-dependent blockade of mechanical allodynia in the rat bone cancer pain model induced by tibia implantation of cancer cells, with the Emax of 57.9% MPE and ED50 of 2.0 mg/kg. Furthermore, lappaconitine treatment stimulated spinal dynorphin A expression in neuropathic rats, and in primary cultures of microglia but not neurons or astrocytes. Intrathecal pretreatment with the specific microglia depletor liposome-encapsulated clodronate, dynorphin A antibody, and κ-opioid receptor antagonist GNTI totally suppressed intrathecal and subcutaneous lappaconitine-induced mechanical antiallodynia. This study suggests that lappaconitine exhibits antinociception through directly stimulating spinal microglial dynorphin A expression. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |